Disease diagnostics involves various laboratory techniques for identification of test samples such as blood and urine for identification and quantification of infective agents. Providing diagnosis based only on symptoms is challenging, as two or more diseases can exhibit similar symptoms and therefore diagnostic tests are used for confirmation of the disease. Diagnostic tests provide rapid and precise results, thereby saving time and providing physicians ample time for treatment.
The global infectious disease diagnostics market is estimated to account for US$ 1,131.4 Mn in terms of value in 2020 and is expected to reach US$ 1,841.2 Mn by the end of 2027.
Global Infectious Disease Diagnostics Market: Drivers
Initiatives to address diagnostic challenges in emerging economies is expected to propel growth of the global infectious disease diagnostics market over the forecast period. For instance, in January 2018, The Foundation for Innovative New Diagnostics collaborated with Becton, Dickinson, and Company (BD), Fondation Botnar, the Global Antibiotic Research & Development Partnership (GARDP), the Drugs for Neglected Diseases Initiative (DNDi), and the South African Medical Research Council (SAMRC) to address antimicrobial resistance (AMR) by accelerating the use of diagnostics.
Global Infectious Disease Diagnostics Market: Opportunities
Public and private initiatives to curb infectious diseases is expected to offer lucrative growth opportunities for players in the market. For instance, in February 2020, Department of Health and Human Services announced a federal grant of US$ 750,000 to the city of Austin to help fight the spread of HIV/AIDS in Texas, U.S.
Global Infectious Disease Diagnostics Market: Restraints
Low awareness and adoption of diagnostic services in emerging economies is expected to hinder growth of the market. For instance, according to GLOBAL AIDS UPDATE 2019 of UNAIDS, in Madagascar, Mauritius, and South Sudan, fewer than 25% of people living with HIV are aware of their status.
The cell cultures segment in the global infectious disease diagnostics market was valued at US$ 362.3 Mn in 2018 and is expected to reach US$ 747.4 Mn by 2027 at a CAGR of 8.3% during the forecast period. Several types of infections can be diagnosed using cell culture, where, microbes are grown in a laboratory setting to identify the same.
The STDs segment held dominant position in the global infectious disease diagnostics market in 2018, accounting for 32.8% share in terms of value, followed by CNS infection, and respiratory infections, respectively. Increasing sexually transmitted disease burden is fueling growth of the segment. Among 20 STDs, the most common are Gonorrhea, Chlamydia, Syphilis, Herpes, Hepatitis (HBV), and Human Immunodeficiency Virus (HIV). For instance, according to Centers for Disease Control and Prevention (CDC), in year 2016, 1,598,354 cases of Chlamydia trachomatis infection were reported in the U.S., corresponding to 497.3 cases per 100,000 in 2015.
Diagnostic centers segment in the global infectious disease diagnostics market was valued at US$ 462.1 Mn in 2018 and is expected to reach US$ 958.7 Mn by 2027 at a CAGR of 8.5% during the forecast period. Central diagnostic laboratories are well equipped with latest diagnostic instruments, and have large resources to carry out multiple tests. Large number of tests are carried out on a daily basis in these centers which supports growth of the segment.
Limited specificity of diagnostic tests available for infectious diseases triggers the need for combined diagnosis, which includes multiple tests. The trend of diagnosing a disease through multiple tests is gaining popularity.
The market in North America is expected to witness significant growth, owing to increasing healthcare expenditure. For instance, according to the Centers for Medicare & Medicaid Services (CMS), health spending in the U.S. is projected to grow at an average rate of 5.5 percent per year for 2018-27 and to reach nearly US$ 6.0 trillion by 2027. However, the reimbursement scenario for diagnostic tests is comparatively poorer.
Global Infectious Disease Diagnostics Market: Competitive Landscape
Major players operating in the global infectious disease diagnostics market include, Becton Dickinson & Company, Cepheid, Inc., Abbott Laboratories, BioMerieux SA, Hologic, Inc., Danaher Corporation, Thermo Fisher Scientific, Inc., Roche Diagnostics, Alera Inc., DiaSorin S.p.A., Quidel Corporation, and Bio-Rad Laboratories, Inc.
Global Infectious Disease Diagnostics Market: Key Developments
March 2020: Chembio Diagnostics, Inc., a point-of-care diagnostics company focused on infectious diseases, completed the technical feasibility phase for a potential companion/compatible diagnostic test being developed in collaboration with Shire Human Genetic Therapies, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
March 2020: GenMark Diagnostics, Inc., a provider of automated, multiplex molecular diagnostic testing systems, submitted an Emergency Use Authorization to the U.S. Food and Drug Administration (FDA) for its ePlex SARS-CoV-2 Test